Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Common Equity: 2011-2024

Historic Common Equity for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $145.5 million.

  • Capricor Therapeutics' Common Equity rose 22.86% to $83.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year increase of 22.86%. This contributed to the annual value of $145.5 million for FY2024, which is 543.60% up from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Common Equity is $145.5 million, which was up 543.60% from $22.6 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Common Equity peaked at $145.5 million during FY2024, and registered a low of $11.8 million during FY2022.
  • For the 3-year period, Capricor Therapeutics' Common Equity averaged around $59.9 million, with its median value being $22.6 million (2023).
  • Per our database at Business Quant, Capricor Therapeutics' Common Equity slumped by 62.43% in 2022 and then soared by 543.60% in 2024.
  • Capricor Therapeutics' Common Equity (Yearly) stood at $28.2 million in 2020, then climbed by 11.23% to $31.4 million in 2021, then slumped by 62.43% to $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then soared by 543.60% to $145.5 million in 2024.